<DOC>
	<DOC>NCT00788151</DOC>
	<brief_summary>This trial will evaluate the use of a tetravalent vaccine against dengue. Primary Objectives: - To describe the immune response to dengue before and after each vaccination with dengue vaccine in two age cohorts of children previously vaccinated with yellow fever (YF) vaccine - To evaluate the safety of each vaccination with dengue vaccine in two age cohorts of children.</brief_summary>
	<brief_title>Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years</brief_title>
	<detailed_description>The control group will receive two doses of placebo and then one dose of Pneumo 23 vaccine for the third vaccination</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 to 11 years on the day of inclusion. Subject in good health, based on medical history, physical examination and laboratory parameters. Provision of Assent Form signed by the subject (for subjects ≥8 years old) and Informed Consent Form signed by the parents or another legally acceptable representative (and by an independent witness for illiterate parent[s]). Subject and parents/legally acceptable representative able to attend all scheduled visits and to comply with all trial procedures. For a female subject of childbearing potential (girls postmenarche), avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to first vaccination, until at least 4 weeks after the last vaccination. Documented receipt of yellow fever vaccine since at least one month before the first vaccination. Exclusion Criteria : Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia. For a female subject of childbearing potential (girls postmenarche), known pregnancy. For a female subject of childbearing potential (girls postmenarche), known pregnancy or positive pregnancy test in blood sample taken at Screening. Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination. Planned participation in another clinical trial during the trial. Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months, or longterm systemic corticosteroids therapy. Known systemic hypersensitivity to any of the vaccines components or history of a lifethreatening reaction to the trial vaccines or to a vaccine containing any of the same substances. Systemic hypersensitivity to YF vaccine or history of a lifethreatening reaction to YF vaccine. Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator. Current or past alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures. Receipt of any blood or bloodderived products in the past 3 months, that might interfere with the assessment of immune response. Receipt of any vaccine in the 4 weeks preceding the first trial vaccination. Planned receipt of any vaccine in the 4 weeks following the first trial vaccination. Human Immunodeficiency Virus, hepatitis B antigen, or hepatitis C seropositivity in blood sample taken at Screening. Clinically significant laboratory abnormalities (as determined by the Investigator) in blood sample taken at Screening. Known previous vaccination with pneumococcal polysaccharide vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dengue virus</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue diseases</keyword>
	<keyword>Dengue vaccine</keyword>
</DOC>